🔗 Share this article

As the US proceeds with historic adjustments to its vaccination schedules, a particular individual has surfaced unexpectedly: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about Covid vaccines during the pandemic and has focused upon possible fatalities following COVID-19 immunization in her brief time at the FDA.

Planned Shifts to Childhood Immunization Schedule

Agency leaders had intended to reveal major changes to the pediatric vaccine schedule in December, aligning the US with Denmark’s national calendar, sources say – a major change that would put the US out of step with a large portion of the world with no evidence for benefit. The announcement has been pushed back until the next year.

Instead of Vinay Prasad, Dr. Høeg is set to address the audience at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

Consolidating Power at the FDA

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for ending some childhood immunization guidelines in the US so as to align more like Denmark's approach, a country with nationalized medicine and a population roughly the population of the state of Wisconsin.

To date statements, she has kept her attention on immunizations – usually the responsibility of Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Qualifications

The appointee has no apparent track record in medication creation, regulation or administrative roles, which has been customary for previous directors of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for leading the CDER, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in running a sizeable institution. She is not an expert in drug approvals.”

Previous directors of CBER would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who led CBER have had.”

CDER has an immense range of responsibilities at the agency, the former commissioner pointed out.

“The public just pays attention on the innovative therapies, but the generic program approves a multitude of generic medications. There is also a biosimilars division, OTC medication office and more, and each of these need to be looked after,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant management component to the position, which oversees over 5,000 personnel. “It is a enormous management job, if you execute it properly,” Woodcock concluded.

Response and Disputed Programs

Regarding inquiries about Høeg’s qualifications and whether this selection indicates more teamwork among FDA leaders on immunizations, a representative stated that the “concerns rely on flawed assumptions”.

“Her resume aligns with the functions of her job,” the representative stated, noting the time Høeg spent counseling the agency head on “drug safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg inherits the agency head's recently launched fast-track approval initiative, a disputed one-day medication authorization process that apparently troubled her former heads. “How are these drugs being picked for this voucher program? Who takes the calls?” Howard asked. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he stated, “the agency looks to be trending towards more relaxed regulations of all drugs, with the exception of immunizations.”

Public History on Vaccines

With immunizations, Dr. Høeg has a clearer, if troubling, track record, Howard have noted. She released a analysis using unverified volunteer-provided data to estimate the frequency of myocarditis following Covid vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “policy goals” for the incoming administration included changing guidelines for new vaccines and ending “non-essential” immunizations, she said post-election on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of preventing teenage boys from receiving Covid vaccines.

“She’s an all-around ideologue who commences with her preconceived notions and reverse-engineers to fit the science in a extremely deceptive, fraudulent manner,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|